Quince Therapeutics, Inc. (QNCX) – What Are Researchers Saying About This Stock?

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have received a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $189.88.

A number of analysts recently weighed in on the stock. Oppenheimer initiated coverage on shares of Quince Therapeutics in a report on Wednesday, July 29th. They issued an “outperform” rating and a $82.00 price objective on the stock. Wall Street Zen lowered shares of Quince Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. Weiss Ratings raised shares of Quince Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 29th. Rodman & Renshaw assumed coverage on shares of Quince Therapeutics in a research report on Thursday, September 24th. They issued a “buy” rating and a $70.00 target price for the company. Finally, Citizens Jmp upgraded shares of Quince Therapeutics from a “market perform” rating to an “outperform” rating and set a $77.00 price target on the stock in a research note on Tuesday, September 22nd.

Quince Therapeutics Stock Performance

NASDAQ QNCX opened at $31.73 on Friday. The stock has a market cap of $32.27 million, a P/E ratio of -0.20 and a beta of 1.33. The company’s fifty day simple moving average is $30.69 and its 200-day simple moving average is $45.07. Quince Therapeutics has a 52 week low of $15.10 and a 52 week high of $909.98.

Quince Therapeutics (NASDAQ:QNCX) last posted its quarterly earnings results on Friday, August 14th. The company reported ($12.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($28.02) by $15.71. On average, research analysts expect that Quince Therapeutics will post -8.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Quince Therapeutics

A hedge fund recently bought a new stake in Quince Therapeutics stock. BlackRock Inc. acquired a new position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,702 shares of the company’s stock, valued at approximately $31,000. BlackRock Inc. owned approximately 0.17% of Quince Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases with significant unmet medical needs. The company is advancing therapies designed to address underlying disease mechanisms and improve outcomes for patients with serious genetic and neurological disorders.

Quince’s lead program is based on the EryDex drug-delivery platform, which uses a patient’s own red blood cells to encapsulate and gradually release a corticosteroid in the body.